ProstACT GLOBAL is assessing the safety and efficacy of 177Lu-TLX591 plus SOC vs SOC alone in patients with mCRPC.
Scott T. Tagawa, MD, MS, FACP, FASCO
Advertisement
Articles by Scott T. Tagawa, MD, MS, FACP, FASCO
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
Urocross shows sustained benefit through 24 months post-removal
2
Updated AUA/SUO Advanced Prostate Cancer guideline emphasizes role of PSMA-PET
3
The Expert APProach: Focal Therapy and Precision Prostate Cancer Care, With Anup A. Vora, MD
4
Sender Herschorn, BSc, MDCM, FRCSC, on vibegron efficacy in older men with OAB and BPH
5